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Systemic lupus erythematosus (SLE) is an autoimmune disease of unresolved cause 
afflicting predominantly women in their 
childbearing years. Speculation exists as 
to the relative roles of viruses, histocompati­
bility loci such as H LA-D R 3, and estrogen- 
mediated decreases in suppressor cell 
function.1,2 Whatever the cause or familial 
tendency, the disease results in a pathologic 
hyperactivity of the B-lymphocyte popula­
tion and a subsequent production of auto­
antibodies. This hyperactivity may reflect a 
primary B-cell defect or a deficiency of 
regulatory cells.2,3 Although the pathogen­
esis of the disease has undoubtedly remained 
unchanged over the past 30 years, the diag­
nosis, maternal prognosis, and obstetric 
implications have changed. In 1955, Turner 
et al.4 remarked that “ Pregnancy is not a 
good omen for women with extensive lupus 
erythematosus.” They expressed the hope 
that the introduction of adrenocorticotropic 
hormone (A C TH ) and cortisone could pro­
long the lives of women affected by SLE. In 
1974, Dubois et al.5 demonstrated improved 
survival rates in association with high doses 
of corticosteroids. Although there has been a 
marked decrease in deaths from central ner­
vous system (CNS) manifestations and ure­
mia, fungal and opportunistic bacterial in­
fections have become an important cause of 
death paralleling the increased utilization of 
steroids, dialyses, and transplantation ther­
apies.
Because of increasing survivorship and 
the natural tendency for SLE to affect wo­
men of childbearing potential, an under­
standing of SLE in pregnancy is of growing 
importance to the obstetrician and the in­
ternist. T o  enhance such understanding, it is 
necessary for us to examine the interrela­
tionships of the disease and pregnancy.
Diagnosis and Manifestations
The diagnosis of SLE is often inhibited by 
its protean manifestations and its tendency 
to periods of exacerbation and remission. 
Specific preliminary criteria for standard­
izing the diagnosis of SLE were proposed by 
Chen et al.6 in 1971. A proposed 1982 
revision of criteria appeared in abstract form 
from Tan et al.7 Both sets of criteria (Table 1) 
require the identification of four or more 
manifestations to establish the diagnosis of 
SLE with a high degree of sensitivity and 
specificity against rheumatoid arthritis, 
scleroderma, or nonrheumatic diseases.6,7
SLE manifestations vary, but arthralgias 
or arthritis present in roughly 90% of pa-
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TA B LE  1. T he Diagnosis o f Systemic Lupus Erythematosus*
1971 Criteria2 Proposed 1982 Revision3
1. Facial erythema, butterfly rash 1. Malar rash
2. Discoid lupus 2. Discoid lupus
3. Raynaud’s phenomenon 3. Photosensitivity
4. Alopecia 4. Oral ulcers
5. Photosensitivity 5. Arthritis
6. Oral or nasopharyngeal ulceration 6. Antibody to DNA or Sm or LE cells
7. Arthritis without deformity or false-positive STS
8. LE cells 7. Proteinuria >  0.5 g/day or
9. Chronic false-positive STS cellular casts
10. Profuse proteinuria >  3.5 g/24 hr 8. Pleuritis and pericarditis
11. Cellular casts 9. Psychosis or seizures
12. Pleuritis and/or pericarditis 10. Hemolytic anemia or leukopenia or
13. Psychosis and/or convulsions thrombocytopenia
14. Hemolytic anemia or leukopenia or
thrombocytopenia
•For each set of criteria, four or more are required for diagnosis of SLE.
dents. Dermatologic manifestations are seen 
in 70-80%, and renal disease is present in 46% 
of patients. Hematologic abnormalities are 
present in more than 50% of cases, but 
cardiovascular disease afflicts 30-50% .x
Of the hematologic aspects, anemia is the 
most common (57-78%) but is most often the 
anemia of chronic disease and not auto­
immune in nature.3 A positive direct 
Coombs test is relatively common, and 
leukopenia is seen in about 50% of patients. 
There is a greater absolute decrease in circu­
lating granulocytes, in part secondary to 
marrow inhibition. A decrease in the abso­
lute number and total proportion of T  and B 
cells is seen, and the decrease in T  cells 
reportedly parallels disease activity.3 Lupus 
anticoagulant (IgG), sometimes associated 
with a chronic false-positive serologic test 
for syphilis (STS), interferes with activation 
of prothrombin by the prothrombin activa­
tor complex and inhibits clotting factor 
interaction on phospholipid surfaces.9 The 
IgG fraction that contains lupus antico­
agulant has been shown to reduce the release 
of prostacyclin and thereby plays a role in 
arterial thrombosis as well as the obstetric 
problem of reduced uterine blood flow and 
repeated intrauterine deaths.9 Some mani­
festations of SLE may be altered by preg­
nancy. Tozman et a l.10 noted significantly 
less pleuritis and pericarditis and a sugges­
tion of less CNS disease when comparing 
pregnant SLE patients with the total SLE 
population. In addition, Varner et al.11 
found the subset of patients in whom SLE 
developed in pregnancy had thrombocyto­
penia and heavy proteinuria more fre­
quently. Indeed, can pregnancy cause an 
alteration in the onset or course, short-term 
or long-term, of SLE?
The first manifestations of SLE may occur 
during pregnancy or the puerperium. Both 
the initial diagnosis of SLE in pregnancy 
and the differentiation of preeclamptic tox­
emia (PET) from SLE nephritis can be 
extremely difficult.11’ 16 PET is often associ­
ated with renal manifestations and may be 
present in 18-25% of all pregnant SLE 
patients.12,14,16 Varner et al.11 found that of 
the 18% of patients in whom symptoms of 
preeclampsia developed, 70% had their dis­
ease first diagnosed in pregnancy. Some feel 
that a renal biopsy in the third trimester is 
relatively contraindicated and the approach 
should be empiric.14 Antinuclear antibody is 
not normally present in sera of normal or 
preeclamptic patients and may therefore 
aid in diagnosis.15 Decreased gestational 
age (27-30 weeks), severity of hypertension, 
severity of renal involvement, anemia, 
thrombocytopenia, coagulation defects, and 
circulating antibodies may be atypical fea­
tures suggesting a coexisting multisystem


































disease.11 Analysis of several studies2,11'17'18 
indicates that of all pregnancies compli­
cated by SLE, 9-21 % first had manifestations 
during pregnancy. Fine et a l.19 believe that 
this is not likely to represent an actual 
increase in the onset of SLE if compared 
with any 1 -year period during the childbear­
ing years.
Effect of Pregnancy on SLE
There is no unanimous agreement as to the 
effect of pregnancy on the frequency of 
exacerbations or worsening of SLE nephri­
tis. It is the current general feeling that a 
pregnancy conceived during a period of SLE 
remission is likely to remain quiescent. 
Conversely, it is less likely to undergo ex­
acerbation.18,20 If exacerbations do occur in 
such cases, they are usually m ild.18 Hayslett 
and Lynn20 found of those in remission for 6 
months before conception, the remission 
persisted in two-thirds; 32% had exacerba­
tions, 10% severe but reversible in nature. If 
conception occurred during active SLE or 
lupus renal disease, the course was more 
severe. The manifestations worsened in 
roughly 50%.
The occurrence of exacerbations in differ­
ent trimesters and the postpartum period
• j  1 ■ - U  ! • *  .  8 ,1 0 ,1 1 ,1 3 ,1 4 ,1 7 ,2 8varies widely in the literature....................
Garsenstein et al.25 formulated the relative 
risk of an exacerbation during either half of 
pregnancy or postpartum by comparing 
these periods to 32 weeks before conception 
and 9-40 weeks postpartum. The number of 
exacerbations or remissions per 100 weeks at 
risk was then calculated for each period. The 
relative risks were roughly 3.3 times those of 
the control period in the first half of preg­
nancy, 1.7 times those of the control period 
in the second half, and almost 7 times those 
of the control period in the postpartum 
period.19
Zulman14 notes that SLE may have a 
profound short-term effect, noting in a liter­
ature review12,14,17,25 that 19 of 20 maternal 
deaths occurred postpartum. The cause of 
such flares and remissions remains un­
29
known, but they are probably dependent 
upon the degree of imbalance between trig­
ger factors and regulatory factors. A post­
partum drop in suppressive factors, a de­
crease in suppressor-cell activity or ab­
normal helper-cell function (or all three) 
could predispose a patient to altered disease 
activity.2 In general, as opposed to pre-1970 
reports, later studies show little or no in­
crease in postpartum SLE activity. Zurier 
comments that the characteristic increase in 
postpartum disease activity is apparently 
decreasing because more mild cases are 
being diagnosed. Additional factors include 
greater experience with steroid therapy and 
a greater general awareness of SLE.29
Bear30 states that pregnancy may lead to 
serious and even lethal activation of SLE 
and/or lupus nephritis. However, most re­
cent reviews indicate that pregnancy does 
not adversely affect the long-term course of 
SLE.14,20,31,32 More specifically, evidence of 
disease activity in the 6 months preceding 
conception predisposed to permanent or 
transient renal function deterioration dur­
ing or after pregnancy.20 Yet in 61% of those 
same pregnancies antedated by the onset of 
SLE, the clinical course of the disease was 
not adversely influenced by pregnancy. This 
is in agreement with the findings of Zul­
man. The long-term course of primary 
renal disease showed no evidence of preg­
nancy-related deterioration or lesion pro­
gression beyond that expected in the non­
pregnant state.32 In general, SLE patients 
who become pregnant have a more favorable 
prognosis than those who do not; however, 
this may well reflect disease severity as it 
relates to the capacity to become preg­
nant. 14,18
Effects of Pregnancy Termination 
on SLE
Having explored the effects of pregnancy on 
SLE, we shall consider the effects of 
pregnancy termination upon SLE. Donald­
son et al.12 noted that of 12 patients for 
whom therapeutic abortions were per-
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formed for acute SLE, only 1 patient 
improved, 11 of 12 had no change or 
experienced disease reactivation, and subse­
quently 3 patients died. It is believed that for 
disease management, induced abortions 
exert little, if any, positive influence on 
subsequent clinical course,21 and there is no 
evidence that therapeutic termination alone 
is “ therapeutic” in a flare.14 It will not 
prevent maternal morbidity.19 By the same 
token, elective pregnancy termination 
should be an option for the patient. Zulman 
et al.14 reported upon 10 patients who opted 
for elective abortions, including 1 with 
active disease, most of whom were given 
supplemental prednisone for 48 hours be­
fore returning to their regular dosage. In 
these cases, no detrimental short-term or 
long-term effects were noted.
Maternal Effects of SLE
SLE exerts influences upon the mother. To  
the disappointment of physicians caring for 
patients 20 years ago when SLE was con­
sidered a “poor omen,” it was noted that 
steroids did not prevent ovulation, although 
amenorrhea was sometimes seen.18 Fertility 
was unimpaired when the disease was under
33 • • 17 26  28control. Several investigators ’ ’ noted 
that sterility and fertility were virtually 
unchanged by maternal SLE. Fraga et a l.17 
found that the overall fertility rate (preg­
nancies per fertile patient) prior to the 
clinical onset of disease was 3.4 and after 
diagnosis, 2.1. When compared with control 
subjects, however, the fertility of SLE pa­
tients was not seen to be significantly 
altered. Involuntary sterility was noted in 
24.5% of patients after the diagnosis and in 
25% of the control group. Although fetal 
effects of SLE are discussed later, it should 
be noted that SLE exerts an adverse effect 
on perinatal outcome before as well as 
after its diagnosis. In one study population, 
there were 23.1% spontaneous abortions 
prior to diagnosis and 40.5% following di­
agnosis. The control group rate was 12.5%. 
Maternal steroid therapy did not improve 
the abortion rate. It has been recommended
that preclinical disease be suspected in 
mothers experiencing recurrent losses, par­
ticularly in black women.31
Patients with SLE have increased ma­
ternal morbidity and mortality. The risks of 
exacerbation as well as the increased risk of 
preeclampsia (18—25%)12’14 were previously 
discussed. Houser et al.23 found that only 
those patients in whom severe preeclampsia 
or nephritis developed exhibited changes in 
renal function status. Despite this finding, 
it was their conclusion that although the 
patient with lupus nephropathy has a high- 
risk pregnancy, the likelihood of an unfa­
vorable outcome in patients without ab­
normal renal function or active SLE seems 
small. When under intensive medical and 
obstetric management, there was no long­
term risk to maternal well-being.23,26 Fine et 
a l.19 found that in 114 pregnancies, only 15 
patients suffered permanent deterioration.22 
In patients in whom SLE developed in 
pregnancy, there was no evidence that the 
subsequent course would be different from 
that expected in the absence of pregnancy.
Earlier reports4,28 stressed increased ma­
ternal mortality, particularly in the face of 
renal or cardiac disease. Subsequently, re­
ports have shown that although pregnancy 
in SLE may exacerbate the disease, there is 
no proof that it leads to increased maternal 
mortality.13,25 Furthermore, in patients with 
renal involvement, there was no significant  ^
difference in deaths due to lupus glomeru­
lonephritis during pregnancy as compared 
with the nonpregnant state.25 The subse­
quent maternal course is regrettably impos­
sible to predict on the basis of the course of 
the disease during a prior pregnancy.18
Fetoplacental Effects of SLE
SLE affects the fetoplacental unit before and
after its clinical recognition. Fetal outcome
is dependent upon disease activity.20,21,23
Most authors would agree that pregnancy
wastage is increased secondary to 
C T  T? 1 1 , 1 5 , 1 7 , 1 9 - 2 1 , 2 3 - 2 5 , 2 7  t j  r  J -  •SLE. Before diagnosis, spon­
taneous abortion estimates range up to 23 - 
30%.11,17 Following diagnosis, spontaneous







































abortions occur in 5-40% of pregnan­
cies.11’17,19’27 The normal spontaneous abor­
tion rale ranging from about 8% to 12.5%.11,17 
Fetal loss is further increased by sequelae 
of prematurity, which occurs in 16.6-37%  
of pregnancies following the diagnosis of
„ T t -  8,1 2 ,1 5 ,1 8 ,2 1 ,2 3 ,2 5  ^  .  ,  T 18SLE. Estes and Larson re­
ported an increased risk of fetal death late 
in pregnancy, and estimates of stillbirths 
range from 12 to 30%,12,22 with fetal wastage 
of 25-33.3%12,21,22,24
Loss is related to maternal disease activ­
ity.11,19 21,23,25 With respect to lupus renal 
disease, a maternal serum creatinine of 1.5 
m g/dl carried a 50% fetal loss rate,20 and a 
maternal BUN greater than 50 m g/dl was 
associated with adverse outcome.19 Houser 
et al.23 found, in patients with previously 
documented lupus nephropathy, that all ten 
pregnancies without clinical renal disease or 
active SLE at conception delivered at term 
and experienced a benign neonatal course. 
In eight pregnancies with clinical renal 
disease or active SLE at conception, only one 
resulted in a term delivery, and three were 
premature. Fine et a l.19 found that although 
there was a minimal effect of pregnancy on 
renal involvement, fetal survival was greatly 
compromised. If proteinuria and decreased 
creatinine clearance were present, preg­
nancy wastage was increased to 80%. On the 
other hand, if patients with lupus renal 
disease were in remission for 6 months 
before conception, the rate of successful live 
births was 92% (comparable to normotensive 
gravidas with diverse types of renal dis­
ease).20 The rate of prematurity did not 
exceed the expected rate.
Aside from pregnancy loss or prematurity, 
what other effects does SLE or its therapy 
exert upon the fetus? No study1 1,13,19,20,23,25 
found any increased incidence of congenital 
anomalies among viable pregnancies. Like­
wise, no increased anomaly rates have been 
related to steroid or immunosuppressive 
therapy. Concordant growth retardation has 
been reported in infants of mothers with 
SLE.19 If one combines two recent series,11’19
13 of 62 (21%) infants were small for gesta­
tional age, 46 of 62 (74%) were appropriate
for gestational age, and 3 of 62 (5%) were 
large for gestational age.
Even after going through the birth pro­
cess, the infant may suffer sequelae related to 
maternal disease. Neonatal SLE is usually 
considered to be a distinct entity from 
“ familial” lupus. The onset of familial 
lupus is usually later in life and, more 
variable in course, and related family mem­
bers have hypergammaglobulinemia.34 The 
two most common manifestations of neo­
natal SLE are dermatologic and cardiac in 
nature. Cutaneous lesions are erythematous, 
scaly, and atrophic, usually involving the 
face and upper thorax, with resolution by 12 
months of age. Congenital cardiac involve­
ment consists of atrioventricular block. It is 
unusual for an infant to have both mani­
festations.35 Transplacental humoral factors 
(ANA) disappear within weeks.15 Hemato­
logic abnormalities such as anemia, leuko­
penia, and thrombocytopenia can exist con­
currently or in the absence of the rash or 
congenital heart block (CH B).35
CHB has a poorer prognosis than the skin 
manifestations.35 The underlying pathology 
is endocardial fibroelastosis, fibrosis of the 
conducting system, and secondary mitral 
insufficiency and/or small patent ductus 
arteriosus.35,36 Fifteen to 20% of these infants 
have associated congenital heart defects.37 
The cause of this condition is speculative—  
perhaps it occurs because of transplacental 
passage of immune complexes or maternal 
antigens that stimulate the fetal immune 
system to form complexes. Injury may occur 
early in gestation (4-6 weeks) during a 
critical period of organogenesis, and the 
nodal anlage then fails to develop normally. 
Alternatively, the definitive atrioventricular 
node develops, is injured, and subsequently 
undergoes fibrosis.38 These infants may re­
quire pacemakers,36 but most who survive 
the neonatal period do relatively well.39 
CHB is a permanent but presumably non­
progressive insult.25 In a review of 42 infants 
with neonatal SLE, only 2 of 23 with the 
cutaneous form were male, whereas 12 of 30 
with the CHB form were male.35 This study 
contrasts with the work of Oleinick,40 who
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found that proximal siblings of SLE pa­
tients had a decreased sex ratio (fewer males 
to females), but offspring of SLE patients do 
not have an altered sex ratio.40,41 Just as 
immunologic factors may dictate the mani­
festations of maternal lupus upon the fetus, 
the placenta is subject to such influences and 
may also affect fetal survival.42'45
Bresnihan et al.44 found that the incidence 
of lymphocytotoxic antibodies in sera of 
SLE patients was significantly lower during 
pregnancies ending in live births than those 
ending in spontaneous abortions. Further­
more, these lymphocytotoxic antibodies 
could be absorbed with trophoblastic anti­
gens, perhaps explaining increased fetal 
loss. The data of Lom-Orta et al.45 is in 
opposition to this, however. Placental histo­
logic and immunofluorescent examinations 
have shown immune complex deposition 
along the trophoblast membrane and necro­
tizing decidua] vasculopathy with fibrinoid 
necrosis.42,43 This may represent one of 
many mechanisms resulting in placental 
ischemia, impaired placental development 
and function, and subsequent fetal growth 
retardation or death.42
Management of Pregnancy 
and SLE
Avoidance of adverse fetal outcome and 
provision of safe maternal-fetal passage 
through pregnancy, labor, and delivery are 
the goals of every obstetrician and internist 
involved in caring for the pregnant SLE 
patient. Realizing these goals requires an 
understanding of the interactions of SLE 
and pregnancy, utilization of laboratory and 
clinical assessments, and a working knowl­
edge of current drug therapy.
Routine obstetric laboratory work may 
aid in diagnosis or indicate disease activ­
ity. As discussed before, 50% of SLE pa­
tients have a hematologic abnormality,8 
usually anemia. Leukopenia, thrombocyto­
penia, and a positive Coombs are not un­
common.3 A chronic false-positive STS 
serves as a major diagnostic criterion and is 
noted in some pregnant SLE patients.6,7,11 A
routine urinalysis and sediment examina­
tion are important tools, because renal dis­
ease is present in almost 46% of SLE pa­
tients.8 Other generally available determi­
nations such as serum creatinine, blood urea 
nitrogen (BUN), creatinine clearance, and 
urinary total protein have been related to 
fetal outcome.19,20 Several,10,14,21,24 but not 
ajj 11,20,21 autjlors £eej that serial complement 
levels are predictive of the course of the 
mother’s disease.
Baines et al.46 found that in normal preg­
nancies the third component of complement 
(C 3) and total hemolytic complement (C H 50 )  
showed gradually increasing activity as 
pregnancy progressed following a signifi­
cant depression in the first trimester. They 
questioned whether this initial decrease in 
complement resulted from increased anti- 
gen-antibody reactions associated with the 
allograft of pregnancy. In a study of com­
plement levels in normal and preeclamptic 
pregnancies, it was found that complement 
levels in preeclamptics at delivery, 1 day 
postpartum, and at 6 weeks postpartum 
approximated the control levels.47
Zurier et al.24 investigated serum comple­
ment levels in pregnancies complicated by 
SLE. Although they did not specifically 
correlate abnormal values with exacerba­
tions, they noted that the mean complement 
values in all trimesters were slightly in­
creased but within normal limits. Tozmanet 
al.10 reported that in inactive SLE, C 3 and 
C H 5 0  rose during pregnancy, but C 3 re­
mained in the normal range. When SLE was 
active, the patients had significantly lower 
C H 50 levels at the onset and throughout 
pregnancy. Devoe et al.21 examined the rela­
tionship of lupus activity and complement 
levels prospectively in 13 pregnancies and 
concluded that exacerbations were signaled 
by decreased or falling levels of complement. 
Remission states were reportedly associated 
with normal or near normal C3 or C 4  levels. 
There was considerable variability in anti- 
nuclear immunofluorescent studies and 
anti-DNA (Farr) assays, leading to the con 
elusion that complement is more useful in 
assessment and prognosis than antinuclear

















































factors. It is interesting to note that a review 
of the data of Devoe et al.21 shows that 
although exacerbations were associated 
with decreased complement levels in six of 
seven exacerbations, one patient had an 
exacerbation with normal C3 and C4. Fur­
thermore, 6 of 26 times complement levels 
were obtained from patients in clinical re­
mission, C 3 and/or C4 were decreased. In 
total, 8 of 33 listed complement levels did 
not correlate with clinical disease activity. 
Varner et al. 11 looked at serial complement 
levels in 1 2  pregnancies and commented that 
C3 did not correlate with the course of the 
disease in 5 of 7 pregnancies with SLE 
exacerbations. C4 paralleled C3 in 10 of 12 
pregnancies. Hayslett et al.20 believe there is 
a poor correlation between the results of 
serologic tests and disease activity. Serial 
anti-DNA titers are of limited usefulness in 
signaling exacerbations or predicting the 
course of the disease. 11 It would appear that 
clinical parameters and renal and hemato­
logic studies are most useful in assessing the 
course of SLE in pregnancy as well as the 
need for medication alteration. 11,20
Clinical obstetric precautions in preg­
nancies associated with SLE are similar 
to those required for competent care of 
other high-risk pregnancies. As in all preg­
nancies, early exhaustive efforts should be 
made to establish firm pregnancy dating. 
This is obviously important in view of 
increased prematurity8,12,15,18,21,23,25 and its 
role in possible intervention decisions. In­
trauterine growth retardation occurs in 
SLE , 11’19 and the early diagnosis and appro­
priate management of this hinges upon 
accurate obstetric dating. Serial ultrasono­
graphic examinations may be indicated. In 
attempts to reduce the high rate of still­
birth, 12,18,22 fetal surveillance consisting of 
electronic fetal heart rate monitoring and 
estriol determinations should be instituted 
at a time when reliable interpretation and 
successful intervention, if indicated, is pos­
sible— usually at 30-32 weeks’ gestation. 11 It 
is important to remember that steroids may 
affect fetal estriol production, but subnor­
mal estrogen excretion in pregnant women
receiving less than 75 mg of cortisol daily is 
indicative of fetal failure to thrive and sub­
sequent growth retardation or stillbirth.48 
As in other high-risk pregnancies, careful 
fetal monitoring should! be employed 
throughout labor. If a maternal antiplatelet 
antibody is present (as is also the case in 
ITP) a fetal scalp platelet count should be 
performed early in labor.49
Delivery for the patient with SLE should 
be individualized and in accordance with 
good obstetric practice. Although the cesar­
ean section rate for SLE patients has been 
reported as high as 59% , 10 Varner et al. 11 
noted a rate of 12.9% (the same as the overall 
institution rate). Delivery for the majority of 
pregnancies completing the second tri­
mester was accomplished spontaneously or 
with elective low forceps. 11 SLE per se is not 
an indication for cesarean section. Further­
more, there is no evidence that cesarean 
section is of benefit in cases of CH B .39
Reduction of postpartum exacerbations 
with intrapartum and postpartum cortico­
steroid augmentation has been cham­
pioned,8 and its use has been frequently 
reported.8,10,11,19,21,25 The usual dosage men­
tioned is 100-150 mg of intravenous hydro­
cortisone every 8 hours, in addition to the 
maintenance dosage until after the first 
postpartum day.8,21 Although some11 would 
question the effectiveness of augmentation 
in preventing a postpartum flare, most 
would favor its prophylactic use.8,10,19,25 It is 
recommended that immunosuppression not 
be decreased in the postpartum period.8,11
Although dialysis19 and plasmapheresis50 
may play a therapeutic role, immunosup­
pressive and anti-inflammatory agents form 
the mainstay of current SLE therapy. It is 
clear that since the introduction of cortico­
steroid therapy, 5-year survival has im ­
proved from 70% to 93% , 19 although cortico­
steroids have had no effect on pregnancy 
outcome. 18 Patients who conceive with 
active disease should receive steroid and, if 
necessary, immunosuppressive therapy as in 
the nonpregnant state. 14 It is agreed that 
there is no justification for alteration of 
needed therapy because of pregnancy. 11,19 Of
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note, Varner et al.11 found that of nine 
pregnancies in which disease worsened, four 
had been advised to decrease medication 
prior to the exacerbation.
Medical management of SLE can poten­
tially produce undesired effects in preg­
nancy. Although the benefits outweigh the 
risks,11'14 physician understanding and sub­
sequent communication of the relative risks 
to patients is important. Aspirin is fre­
quently used but may induce bleeding in 
patients with circulating anticoagulants. 
Furthermore, in a review, high-dose aspirin 
consumers had longer gestational length, 
longer labor, an increased incidence of post­
maturity, and increased blood loss.51 Cyto­
toxic drugs are sometimes used in preg­
nancy. Although the risk of a malformed 
viable infant following the first-trimester 
administration of a cytotoxic drug must be 
considered, no reproducible anomaly has 
been reported in humans. For drugs admin­
istered in the second and third trimester, the 
risk of a fetal malformation is no greater 
than normal. Importantly, 40% of babies 
born after cytotoxic drug administration are 
low in birth weight, and no follow-up 
studies of their fertility are available.52
Azathioprine is a purine analog, felt to be 
a “steroid-sparing” agent with less im­
munosuppressive and more antiinflamma­
tory activity than cyclophosphamide.51,53 
Sudden withdrawal of azathioprine can 
cause a severe refractory exacerbation.19,51 
Follow-up karyotype examinations, intel­
ligence testing, and neurologic examina­
tions in infants of mothers receiving azathi­
oprine have revealed no abnormalities.53 
The skeletal system of laboratory animals 
appears to be the primary target of azathio­
prine as a teratogen; yet only one case of 
pre-axial polydactyly has been reported in 
association with its use.54 It appears that 
azathioprine use is relatively safe in preg-
53,54nancy.
Beneficial maternal effects of steroids were 
previously discussed, but with their use 
should come the realization that there is a 
relationship between corticosteroids and 
infection. Infection is now a leading cause of
death among SLE patients.5 Although glu­
cocorticoids in combination with immuno­
suppressive drugs may cause decreased 
thymic size and a slight decrease in the 
neonatal lymphocyte count,19 adverse fetal 
effects are rare. There have been a few reports 
of reduced fetal growth, but no report shows 
an increased human incidence of cleft lip or 
palate.19 The human placenta converts a 
large fraction of prednisone and predniso­
lone to inactive 11-keto forms, but not 
dexamethasone or betamethasone.55 The re­
sultant concentrations of these steroids dic­
tate that prednisone or prednisolone, not 
betamethasone or dexamethasone, be used 
to treat maternal diseases.56 Prednisone and 
other steroids are secreted in breast milk. 
Although a maternal prednisone dosage of 
less than 30 mg/day is unlikely to create 
problems,57 breast-feeding while on gluco­
corticoids or azathioprine is to be discour­
aged.19,57
Family Planning
Traditionally, the postpartum period has 
been a time to discuss contraception and 
family planning. Warnings have been given 
that the increased exertion associated with 
child care may tax the mother and thereby 
increase her risk for increased disease activ­
ity.58 T o avoid undesired pregnancy, indi­
vidualized careful consideration should be 
given to safe contraception. The fear has 
been expressed that the use of intrauterine 
devices, particularly in immunosuppressed 
patients, poses undue risk of infection.11,58 
Use may also result in increased tissue 
damage and elevated antibody formation.58 
Oral contraceptive pills have been associ­
ated with thrombosis, hypertension, and 
possible disease exacerbation. The use of the 
traditional condom plus a spermicide or 
diaphragm has seemed prudent. Recently, 
support for this view was produced.58 In 
summary, the use of estrogen-containing 
compounds, even at low doses (30-50 i^g), 
should be avoided in women with SLE. 
When reversible contraception is chosen 
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pregnancy, mechanical methods should be 
tried initially. If this is not possible, pure 
progestogens may be valuable because of 
antigonadotrophic and antiestrogenic ef-
r .  59fects.
Routine gynecologic care should include 
regular Papanicolaou (Pap) smears. In a 
recent series,11 3 of 38 pregnancies showed 
abnormal results in Pap smears, and all 3 
women were using immunosuppressive 
agents. Immunosuppression is known to 
predispose the human cervical epithelium 
to dysplastic change.
Conclusions
SLE in pregnancy is a high-risk condition 
for both the mother and the fetus, demand­
ing intensive and aggressive obstetric and 
medical management. Through improve­
ments in therapeutic regimens, more fre­
quent diagnosis of milder cases, and dili­
gent obstetric surveillanceand management, 
the maternal and fetal prognoses appear 
to be improving. Ideally, patient education 
should occur at initial diagnosis; then preg­
nancies, if desired, should be planned dur­
ing periods of remission. Educated about the 
maternal and fetal implications of the dis­
ease, the patient is better prepared both for 
the intensive observation needed and pos­
sible obstetric or neonatal complications 
that might occur.
Successful management of such preg­
nancies requires a team approach linking 
the obstetrician and the internist. It is rec­
ommended that patients with SLE in preg­
nancy undergo serial clinical evaluations 
using ARA criteria and careful scrutiny for 
development of PET. Maternal monitoring 
should include routine obstetric laboratory 
work as well as evaluation of hematologic 
and renal indices. Complement level de­
terminations are favored by some, but the 
Farr assay appears to have little predictive 
ability. Careful pregnancy dating should be 
obtained, and fetal surveillance should be 
instituted as soon as the potential exists for 
fetal salvage. The route of delivery should be 
based upon appropriate obstetric indica­
tions. The postpartum period is a high-risk 
period for exacerbation of the condition, 
and prophylactic steroids may be beneficial 
in reducing this risk. Finally, it appears that 
barrier methods of contraception are the 
safest reversible forms of family planning 
for patients with SLE.
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